Jason M. Hafron, M.D., Partner and Director of Research, Michigan Institute of Urology, P.C.; Associate Professor of Urology, William Beaumont School of Medicine, Oakland University; Director of Robotic Surgery, William Beaumont Hospital, Royal Oak, Mich.
Articles by Jason M. Hafron, M.D., Partner and Director of Research, Michigan Institute of Urology, P.C.; Associate Professor of Urology, William Beaumont School of Medicine, Oakland University; Director of Robotic Surgery, William Beaumont Hospital, Royal Oak, Mich.
Upper tract transitional cell carcinoma: Diagnostic and therapeutic considerations
ByRaoul S. Concepcion, MD,Jason M. Hafron, M.D., Partner and Director of Research, Michigan Institute of Urology, P.C.; Associate Professor of Urology, William Beaumont School of Medicine, Oakland University; Director of Robotic Surgery, William Beaumont Hospital, Royal Oak, Mich.,Joelle Hamilton, MD,Jeremy D. Handel, MD Determining grade of disease is important, as nephron-sparing approaches may be feasible.
